Eli Lilly pauses phase III Activ-3 covid-19 antibody (bamlanivimab) trial for safety reasons

Trial (n=326) has been put on hold for safety reasons after 5 days of treatment, and a week after application was made for a US emergency use authorisation. Lilly said study had “reached a predefined boundary for safety at day 5”; no further details have been released.

British Medical Journal